Bonaventura, Aldo http://orcid.org/0000-0002-4747-5535
Vecchié, Alessandra
Dagna, Lorenzo
Tangianu, Flavio
Abbate, Antonio
Dentali, Francesco
Article History
Received: 30 July 2021
Revised: 14 November 2021
Accepted: 13 January 2022
First Online: 3 February 2022
Declarations
:
: Aldo Bonaventura received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 AHA Scientific Sessions and receive honoraria from Effetti s.r.l. (Milan, Italy) to collaborate on the medical websiteExternalRef removed. Alessandra Vecchié received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 AHA Scientific Sessions and receive honoraria from Effetti s.r.l. (Milan, Italy) to collaborate on the medical websiteExternalRef removed. Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Galapagos, GlaxoSmithKline, Kiniksa, Novartis, Pfizer, Roche, Sanofi-Genzyme, and SOBI. The Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) received unrestricted research/educational grants from Abbvie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline,Janssen, Kiniksa, Merk Sharp & Dohme, Mundipharma Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi Genzyme, and SOBI. Antonio Abbate has received research support from Kiniksa, Novartis, Olatec, R-Pharm, Serpin Pharma, and has served as an advisor to Abiomed, Cromos Pharma, Effetti, Eli Lilly, Implicit Bioscience, Novo-Nordisk. The remaining authors have nothing to disclose related to this study.
Free to read: This content has been made available to all.